Hepatitis B Core Related Antigen - Does it meet our expectations? Evidence from Cohorts in the United Kingdom and South Africa

Louise O Downs[1,2], Marion Delphin[3], Marije van Schalwyk[4,], Susan Hugo[4],
Shiraaz Gabriel[6], Sheila Lumley[1,2], Elizabeth Waddilove[3], Tingyan Wang[1],
Catherine De Lara[1], Arran Babbs[2], Sue Wareing[2], Polyxeni Fengou[2],
Monique I Andersson[2,7], Richard Glashoff[5], Jacqueline Martin[8], M. Azim Ansari[1],
Kosh Agarwal[9], Geoffrey Dusheiko[9], Jantjie Taljaard[4,], Wolfgang Preiser[10],
Eleanor Barnes[1,8], Gavin Kelly[3], Ivana Carey[9], Tongai Maponga[10], Philippa C Matthews[3,11]

1. Nuffield Department of Medicine, University of Oxford, UK
2. Department of Infectious Diseases and Microbiology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
3. The Francis Crick Institute, 1 Midland Road, London, UK
4. Division of Infectious Diseases, Department of Medicine, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa
5. Division of Medical Microbiology & Immunology, Stellenbosch University and National Health Laboratory Service Tygerberg Business Unit, Cape Town, South Africa
6. Division of Gastroenterology and Hepatology, Department of Medicine, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa
7. Radcliffe Department of Medicine, University of Oxford, Oxford, OX1 3AZ, UK
8. Department of Hepatology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
9. Institute of Liver Studies, King's College Hospital, London, UK
10. Division of Medical Virology, Stellenbosch University and National Health Laboratory Service Tygerberg Business Unit, Cape Town, South Africa
11. University College London Hospitals, London, UK

Key words: HBV, hepatitis B, surveillance, monitoring, biomarker, HBcrAg, core related antigen, reservoir

ABSTRACT

Introduction: Hepatitis B virus (HBV) infection is a pressing global public health threat, responsible for increasing mortality with a disproportionate impact on populations in the WHO African region. There is a need for evaluation of new biomarkers that may be able to provide insights into risk stratification and disease pathogenesis. We therefore set out to evaluate Hepatitis B core related antigen (HBcrAg), in cohorts in the United Kingdom (UK) and South Africa (SA).

Methods: We undertook a cross-sectional retrospective observational study, using serum samples obtained from adults living with chronic HBV infection enrolled at Oxford University Hospitals (OUH) NHS Foundation Trust in the UK (n=142), and from a clinical cohort in Cape Town and Bloemfontein, SA (n=211). We recorded routine clinical and laboratory parameters gathered at each site, and undertook quantification of HBcrAg and host immune biomarkers, IL-21, IP-10 and PD-1. We report on HBcrAg distribution, relationship with other clinical and immunological biomarkers, and performance as a risk stratification tool in each setting.

Results: Sex and age were comparable between SA and UK cohorts (p>0.05). There were significant differences between cohorts in ethnicity (p <0.001), HIV coinfection (2.3% in UK vs 56% in SA, p<0.001), HBeAg-positivity (12% in the UK vs 29% in SA, p<0.001), and proportion with HBV DNA >200,000 IU/ml (6% in the UK vs. 22% in SA, p<0.001). Host immune markers were all significantly higher in the SA vs UK cohorts (p<0.001 for all);
(i) HBcrAg was positively associated with HBV DNA in both cohorts (p<0.0001), and in the UK this relationship was mediated by HBeAg-positivity.
(ii) HBcrAg was also positively associated with overall liver inflammation assessed by ALT (p<0.001 in UK, p<0.01 in SA), however there was no specific significant correlation with more precise host immune markers, IP-10, IL-21 or PD-1 (p>0.05 in all cases).
(iii) In univariable and multivariable analysis, there was no association between HBcrAg and liver fibrosis using elastography, APRI or FIB-4 scores in both cohorts.
Discussion: In spite of similar HBcrAg levels in both the UK and SA cohorts, prediction of HBV VL seems to differ depending on settings, suggesting a more tailored and personalised approach to HBcrAg testing is required. In our cohorts, HBcrAg did not correlate with any liver disease outcomes.

INTRODUCTION

A WHO report published in 2024 estimated 254 million people worldwide are living with chronic hepatitis B infection (CHB), resulting in ~1.1 million deaths per year as a result of liver disease, including cirrhosis and hepatocellular carcinoma (HCC) (1). There is a shortage of reliable, accessible and affordable clinical tools to predict outcomes of CHB, so new approaches are being explored to enable enhanced disease prediction. More precise identification of people at risk of liver complications will allow individualised interventions, such as enhanced surveillance or treatment, as well as potentially informing population-level services, resource allocation and development of public health programmes. Evidence that supports these interventions will contribute to progress towards international targets for hepatitis B virus (HBV) elimination as a global public health threat by 2030 (2).

Until March 2024, national and international HBV treatment guidelines stratified patients for antiviral therapy with nucleos/tide analogue (NA) drugs based on a combination of serum markers and liver imaging (3,4). Hepatitis B 'e' antigen (HBeAg) positivity, high HBV DNA viral load (VL) and high hepatitis B surface antigen (HBsAg) titres are all associated with progression to cirrhosis and HCC (5–7), but these tools are imperfect predictors of outcome, and not widely available across all settings due to infrastructure and resource constraints. The landscape is now changing as new WHO guidelines on the management of HBV released in March 2024 progressively relax criteria for treatment (8), such that a wider population are becoming treatment eligible using a less complex algorithm. This shift leads to a call for cheaper and more widely accessible tools for monitoring, and predictors of outcomes that can be applied to those both on and off NA treatment.

NA agents control HBV replication by inhibiting the viral reverse transcriptase (RT) enzyme, thus abrogating production of new HBV DNA genomes and secretion of new infectious virions. However, NA treatments have no direct influence on the intracellular viral reservoir in the form of covalently closed circular (ccc)DNA, and rebound viraemia therefore typically occurs if treatment is stopped. Direct monitoring of cccDNA levels currently requires invasive investigations and thus is not possible in routine clinical practice.

The hepatitis B core related antigen (HBcrAg) is a novel composite marker, combining HBeAg, hepatitis B core antigen (HBcAg), and a small 22kd protein called p22cr (9). It has been defined as a marker of active viral transcription (9,10), correlating with peripheral HBV VL and HBeAg status (10), and there is ongoing work to determine the utility of HBcrAg in predicting liver fibrosis and HCC, either in conjunction with existing approaches to stratification or independently, particularly when HBV VL is low (or quantification is inaccessible). HBcrAg has been increasingly associated with overall markers of liver inflammation (APRI, FIB4 and ALT (11,12)) and liver disease outcomes such as fibrosis and necroinflammation (13) or even predicting HCC (14) or flares after treatment cessation (15). However results seem to differ between populations studied, especially depending on HBeAg status.

To date, the majority of studies investigating HBcrAg are in Asian populations and focused on HBV genotypes B and C, or in Europe. To date, there is only one study of HBcrAg in an African population from the Gambia, which showed that HBcrAg predicted clinically important HBV VL thresholds (16).

Looking forward, a point of care test (POCT) for HBcrAg is being developed, with the potential for supporting risk assessment, particularly in situations where laboratory tests or imaging are not available (17). A POCT also would provide a faster turnaround of diagnosis result, which is associated with a strong increase in successful linkage to care (from 34 to 86% (18)).

Here we present data from two cohorts of distinct geographical locations, the United Kingdom (UK) and South Africa (SA), with two specific aims. First, we set out to generate an observational cross-sectional analysis of the variation of HBcrAg within and between cohorts in these two settings and to describe its relationship with host characteristics and two baseline clinical biomarkers (HBeAg, HBV DNA). Second, we undertook analysis to determine how HBcrAg might be associated with (1) overall liver inflammation (ALT) and circulating immune biomarkers (PD-1, IL-21 and IP-10, which are known to be correlated with liver disease outcomes and/or immune exhaustion (19–21)), (2) disease progression, including fibrosis and cirrhosis (assessed using APRI, FIB-4 and elastography scores), and (3) risk assessment for prevention of mother to child transmission (Figure 1). On this basis, we discuss the real world use of HBcrAg based on its role as a biomarker, to support delivery of interventions for HBV surveillance, treatment and prevention.

Methods

Patient selection and metadata

We undertook a cross-sectional retrospective observational study, using serum samples obtained from adult patients with CHB enrolled at Oxford University Hospitals (OUH) NHS Foundation Trust (UK, n=142), and from the 'OXSA-Hep' Cohort in Cape Town and Bloemfontein, South Africa (SA; n=211). Study settings and recruitment have been previously described for the UK (22,23) and SA (24–26). All participants provided written informed consent. Samples were transported to the research laboratory within 2-3 hours of collection, spun to separate serum and frozen in aliquots at -80°C. We recorded patient demographics, ALT, presence of HIV and elastography scores from routine clinical and electronic patient records.

We calculated laboratory fibrosis scores using the following formulae:

AST to Platelet Ratio Index (APRI): $= \frac{AST(IU/L)/AST\ ULN}{Platelets\ (10^9/L)}$

Fibrosis-4 (FIB-4) $= \frac{Age\ (years)\ x\ AST\ (U/L)}{Platelets\ (10^9/L)\ x\ \sqrt{ALT(U/L)}}$

AST upper limit of normal (ULN) set as 40 U/L as per reference ranges from each individual country laboratory.

The serum sample collection date was designated 'baseline', and metadata including ALT, elastography scores and markers for calculation of non-invasive liver scores were collected as close to baseline as possible, with a limit of 12 months either side of this date.

Ethics approval was provided by Oxford Research Ethics Committee A (reference 09/H0604/20 and N17/01/013), University of Oxford Tropical Research Ethics Committee (ref. OXTREC 01–18), Stellenbosch University Health Research Ethics Committee (HREC ref. N17/01/013), and the University of the Free State Research Ethics Committee (HSREC ref. 203/2016).

Quantification of standard serum HBV parameters

Platforms used to measure routine clinical laboratory biomarkers in the Oxford cohort (UK) and Stellenbosch/Bloemfontein cohort (SA) are listed in Suppl. Table 1. Assays were undertaken on validated clinical diagnostic platforms according to the manufacturers' instructions.

HBcrAg Measurement

Quantitative levels of HBcrAg were determined using a chemiluminescent assay (Lumipulse G HBcrAg assay, Fujirebio) at King's College Hospital NHS Foundation Trust, London, UK. The assay has a linear measurement range of 3-7 $\log_{10}$ U/mL, using 3 $\log_{10}$ U/ml as the lower limit of detection (as recommended by the manufacturer). Samples generating HBcrAg measurements >7 $\log_{10}$IU/ml were diluted (1:5, 1:100 or 1:1000 in TBS).

Thresholds for biomarkers and liver elastography

We used thresholds for analysis based on existing precedents and clinical guidelines. HBV DNA levels >2000 IU/mL, >20,000 IU/mL and >200,000 IU/mL, are used clinically to determine eligibility for antiviral treatment and/or prophylaxis (27). Varying ALT thresholds are applied in different settings, with stringent thresholds for the upper limit of normal (ULN) set as 19 IU/L in females and 30 IU/L in males in 2024 WHO guidelines (8), versus a more relaxed ULN of 40 IU/L (irrespective of sex) suggested elsewhere (3). The new HBcrAg POCT has a HBcrAg laboratory cut-off of approximately ≥4.3 ($\log_{10}$U/ml) (17), and thus we applied this as a pragmatic binary cut-off. We set out to explore, in each of our two cohort settings, the sensitivity and specificity of a positive HBcrAg POCT in predicting clinically significant thresholds that are applied to inform intervention, either in the form of enhanced surveillance, treatment or prophylaxis We set other HBcrAg thresholds based on those previously determined in The Gambia associated with relevant HBV DNA thresholds (16), where HBcrAg 3.6 $\log_{10}$U/ml, 4.8 $\log_{10}$U/mlL and 5.3 $\log_{10}$U/ml were predictive of HBV DNA >2000 IU/mL, >20,000 IU/mL and >200,000 IU/mL, respectively (27).

The presence of liver fibrosis was defined by Fib-4 ≥1.45, APRI >0.5 or elastography score >7kPa, while cirrhosis was based on Fib-4 ≥3.25, APRI > 1 or elastography score ≥12.5kPa as per 2024 WHO guidelines (8).

Cytokine quantification

We quantified IL-21, IP-10 and PD-1 using multiplex ELISA (K151AEL-1, MesoScaleDelivery) using 50uL of serum diluted 1:1 according to the manufacturer's instructions. On each plate, 40 samples were quantified side by side with assay standards, in duplicates. The dynamic ranges for the assay were the following: IL-21 (1.2-12,600 pg/mL), IP-10 (0.49-6,000 pg/mL) and PD-1 (0.11 - 2,200 pg/mL).

Data Analysis and Statistical Methods

We used R version 4.2.0 for statistical analysis. The genetic, clinical, epidemiological, and environmental landscape of our two settings is not comparable, with multiple unmeasured influences which could contribute to immunological profiles and infection outcomes. Accordingly, preliminary analysis demonstrated a different risk profile for HBcrAg in UK vs SA, and on these grounds we did not pool data for SA and UK cohorts, but analysed each independently. We compared the findings between the two settings to review whether similar assumptions and uses of HBcrAg can be applied uniformly in different geographical populations.

(i) Descriptive statistics

We produced descriptive statistics for each cohort including median and interquartile ranges for patient demographics, HBV biomarkers and immune markers. We generated comparative statistics within each cohort using Pearson's, Chi-squared test and Wilcoxon rank sum test. We also undertook analysis of two distinct subpopulations within each cohort, based on a specific rationale about the potential utility of HBcrAg in each.

> **HBeAg-negative**: In individuals who are HBeAg-positive, HBcrAg levels are likely to be dominated by HBeAg and independent measurement of HBcrAg as a biomarker may therefore not add any additional value. However, we hypothesised that HBcrAg may provide useful additional characterisation within the HBeAg-negative subpopulations.

> **Undetectable VL:** HBV DNA is an established biomarker that associates with long-term outcomes, and when this can be measured it remains the gold standard. However, among individuals on treatment, and in a subset of those untreated, HBV DNA is below the threshold for quantification (defined here as <20 IU/ml). Therefore we speculate that HBcrAg could have a role in monitoring these individuals.

(ii) Univariable analysis of relationship between HBcrAg and other parameters

Within each cohort we described the distribution of HBcrAg, and explored the relationship between HBcrAg and individual demographic factors (age, sex), routine laboratory biomarkers (HBeAg, HBV DNA and ALT), immune biomarkers (IL-21, IP-10 and PD-1), and liver fibrosis scores (elastography, Fib-4 and APRI).

(iii) Ability of HBcrAg levels to predict clinically important HBV DNA levels

We assessed the sensitivity and specificity of previously defined HBcrAg levels (3.6, 4.8 and 5.3 $\log_{10}$U/ml) to predict clinically important DNA thresholds (2000, 20,000 and 200,000 IU/ml), in

those currently off antiviral therapy, with particular focus as a risk-stratification tool in a clinical setting to determine eligibility for antenatal prophylactic antiviral therapy.

(iv) Focused multivariable analysis

We accounted for age, sex, HBeAg status, treatment status and HBV DNA levels in a multivariable model to investigate the extent to which HBcrAg could predict presence of liver inflammation (based on ALT) fibrosis and cirrhosis (based on elastography, FIB-4 and APRI scores) (28). For each measure of liver outcome we independently fitted a binomial generalised linear model with those covariates as main effects along with HBcrAg, cohort and their interaction, and binary liver outcome as the dependent variable. The strength (log-odds ratio) and significance of the association between HBcrAg and liver outcome (stratified by cohort, and compared between cohort) were calculated using bias-reduced score by the `brgrlm` R package. We used complete cases only - patterns of missingness therefore varying between the different measures of outcome.

Results

i) HBV cohort in SA is characterised by higher HBeAg prevalence, higher viral loads and higher rates of HIV coinfection compared to the UK

We generated HBcrAg measurements from 353 samples (142 from the UK and 211 from SA); (**Table 1, Figure 1**). Sex and age were comparable between cohorts (p>0.05). However, as anticipated, the cohorts differed in other important ways according to the setting: 68% of SA participants were black African, in contrast to more diverse ethnicities in the UK cohort (p <0.001). Compared to the UK, a higher proportion of the SA population were living with HIV coinfection (56% vs 2.3%, p<0.001), were HBeAg positive (35% vs 12%, p<0.001), and had HBV DNA >200,000 IU/ml (29% vs 12%, p<0.001), although median HBV DNA levels did not significantly differ between cohorts (p=0.3); **(Table 1).** Reflecting these differences (particularly based on HBeAg-positivity, and HIV coinfection), a higher proportion of PLWHB were receiving antiviral treatment in SA 129/197 (65%) compared to the UK, 42/137 (35%); (p <0.001; **Table 1**).

(ii) Liver inflammation is consistent between cohorts, but circulating immune markers (IP-10, IL-21 and PD-1) are significantly higher in the SA vs UK cohort

Overall liver inflammation quantification (ALT) was not significantly different between the SA and UK cohort (p=0.4). IP-10, IL-21 and PD-1 were measured in 153 individuals (93 from SA, 60 from

UK). Median cytokine levels were all significantly higher in the SA vs UK cohort (IP-10: 562 pg/mL vs 296 pg/mL respectively, PD-1: 115 pg/mL vs 27 pg/mL respectively, and IL-21: 10 pg/mL and 1 pg/mL respectively, all p<0.001) (**Supplementary Figure 1**).

Collectively, these findings highlight significant differences in clinical, biological and treatment landscapes between settings.

(iii) Distribution of HBcrAg correlates with age, HIV status, HBeAg status and HBV DNA however overall median HBcrAg does not differ between SA and UK cohorts

The distribution of HBcrAg varied between UK and SA populations **(Figures 2A and 2B),** and although there was no significant difference in median HBcrAg between the UK and SA populations (3.4 $\log_{10}$U/ml vs 3.57 $\log_{10}$U/ml respectively, p=0.1, **table 1),** a greater proportion of those in the SA cohort had HBcrAg ≥5.3 $\log_{10}$U/ml (33% in SA vs 9.2% in UK, **table 1**).

On univariable analysis, HBcrAg was not associated with sex (p>0.05), but had a significant negative association with age (p<0.05 in both cohorts; **Table 2**). As expected, in both the UK and SA cohorts, HBcrAg significantly differed between those who were HBeAg positive and negative (**Figures 2C and 2D,** p<0.001). Median HBcrAg was significantly higher in those who were living with HIV co-infection compared to those without HIV infection in the SA (p <0.001 in SA, and p = 0.11 in UK, **table 2**) but we did not have the numbers required to investigate these differences in the UK cohort.

Regarding the relationship of HBcrAg with HBV viral load, a significant positive correlation was found in both the UK and SA cohorts (R^2 0.41 and 0.7 respectively; p <0.001 for both cohorts; **Table 2**, **Figure 3A, 3B**). However, in the UK cohort, this correlation was lost when considering only the HBeAg negative population (**Figure 3C and 3D**); and in the SA cohort, median HBcrAg was significantly lower in those with undetectable vs detectable HBV DNA (3.1 vs 5.7 $\log_{10}$U/ml, p<0.001, **Figures 2E and 2F**).

(iv) Relationship between HBcrAg and laboratory biomarkers, fibrosis scores and immune markers

We observed a significant positive correlation between HBcrAg and ALT in both UK and SA populations (R^2= 0.38, p < 0.001 and R^2 = 0.2, p = 0.01 respectively, **Figure 4A, 4B**). Building on

this finding, we explored the relationship between HBcrAg and circulating levels of cytokines known to be involved in liver inflammation or exhaustion of the immune compartment, IP-10, IL-21, and PD-1 (**Figure 4C-H**). None of these cytokines were associated with HBcrAg levels in either the UK or SA populations (p>0.05 in all cases), **Figure 4C-H; Table 2**), suggesting a lack of correlation with systemic markers. Finally, there was no significant correlation between HBcrAg and liver stiffness scores, using elastography, Fib-4, or APRI, in either cohort.

(v) Use of CrAg to predict clinically relevant HBV DNA levels

HBcrAg of ≥5.3 $\log_{10}$U/ml was 100% sensitive and specific at identifying those with HBV DNA >200,000 IU/ml in the UK population, but performed less well in the SA population (88%). However, at lower viral loads, in both the UK and SA, the performance of HBcrAg to predict HBV DNA deteriorated, but remained higher in the SA population throughout **(table 3)**.

(vi) Multivariate model to establish HBcrAg association with liver disease outcomes

We conducted a multivariable model analysis to determine the magnitude of association of HBcrAg with different liver health indicators across our study populations (**Table 4**). This model accounted for several covariates identified as potential confounders or predictors of outcome in univariable analysis, including age, sex, HBeAg status, treatment status and HBV VL. The computed odds of liver outcomes were not significantly different between the cohorts (**Table 4**) and there was no significant correlation with any outcome and HBcrAg (**Table 4**).

DISCUSSION

Summary of rationale and findings

We here set out to describe the distribution of HBcrAg in two geographically and ethnically distinct populations, to determine its relationship with other demographic, clinical and immunological parameters. HBcrAg is a new biomarker that may help to predict outcomes of infection and/or treatment in people living with CHB (9,14,29).

As mentioned, HBcrAg is a composite marker, combining HBeAg, hepatitis B core antigen (HBcAg), and p22cr (9), hence HBeAg has a considerable influence over HBcrAg quantification. Some differences in HBcrAg levels observed between our populations are therefore likely to be due to varying HBeAg status. For example, the UK population had significantly fewer HBeAg positive individuals than the SA population, and a lower median HBcrAg level, although this was

not significant (3.40 $\log_{10}$U/L vs 3.57$\log_{10}$U/L respectively, p = 0.1). The only previous study on HBcrAg in Africa in the Gambia found a median of 4.0 $\log_{10}$U/mL (16), which is similar to that of our SA cohort, however only 13% of their population was HBeAg positive (as compared to 29% in our SA cohort). This suggests other parameters such as genotype and environmental or host factors might influence HBcrAg production independent of HBeAg, allowing HBcrAg to aid patient stratification in HBeAg negative populations. Interestingly, HBcrAg significantly positively correlated with HBV DNA in both our study populations, and this correlation was lost on excluding the HBeAg positive population in the UK, but not in SA (Figure 3), similarly to what has been previously observed (16).

With new WHO guidelines expanding treatment eligibility, a larger proportion of PLWHB linked to care will access NA therapy. HBV DNA and ALT measurement are now deemed sufficient alone or together for diagnosis and monitoring, however, not all laboratories or hospitals have the capacity, capability or money required to conduct these molecular assays. We suggest that serological assays may be better suited, and HBcrAg could aid patient monitoring when HBV DNA measurement is not possible or upon drug induced aviraemia, but thresholds may require adaptation in different geographical populations. Here, HBcrAg levels were similar regardless of whether HBV DNA was detectable in the UK cohort (p = 0.41), and although HBcrAg was significantly lower when HBV DNA was undetectable in SA (p<0.001), median HBcrAg in this group was still above the threshold of detection (median 3.1 $\log_{10}$U/ml).

Ultimately, HIV co-infection may have an important influence on HBcrAg due to its effect on both HBeAg positivity and HBV DNA viral load, which in turn are influenced by inflammatory status, microbiome and immune activation. However, we did not have the numbers required in both our populations to address this issue.

Clinical utility of HBcrAg

(i) Predicting liver disease outcomes

We did not show a significant correlation between HBcrAg and liver fibrosis/cirrhosis measurements, using APRI or Fib-4 or elastography. For liver inflammation, ALT levels were correlated only in univariate analysis, and further investigation did not reveal any significant associations between HBcrAg and specific immune circulating markers of inflammation such as IP-10, IL-21, or PD-1. Further work is ongoing to better characterise the immune profiles of these patients.

There are some discrepancies between our findings and existing literature (13,29,30). Elastography and ALT were previously correlated with HBcrAg levels in a similar cohort (16) which however did not compute odds using other liver disease biomarkers. These inconsistencies may reflect differences in (1) fibrosis assessment methodologies (e.g. histological METAVIR analysis vs. circulating marker scores), (2) study populations (notably, our inclusion of South African patients versus predominant focus on Asia and Europe in other cohorts), and (3) disease stages, where the presence or absence of HBeAg has been noted to influence correlations in previous studies.

(ii) Predicting HBV DNA VL for risk stratification in PLWHB

While we have not evaluated the HBcrAG POCT test in this study, based on a HBcrAg threshold of 4.3 $\log_{10}$ U/ml that would correspond with a positive POCT, we postulate it would be highly sensitive at identifying mothers at highest risk of vertical transmission in the UK population, but this is less true for the SA population. These results suggest that the HBcrAg POCT may not function equivalently in geographically distinct populations, and more refined local thresholds may be needed.

Furthermore, as WHO guidelines have changed to allow wider offering of NA therapy based on existing assessment tools and criteria, it is unclear whether there is a need for further practical development of new tools reflecting HBV viral load such as the HBcrAg POCT, or whether this could add unnecessary cost and complexity to clinical assessment. It is worth noting however that current tools for diagnosis require lengthy periods of time for the results (often days, most often weeks), whilst POCT results are given on-site. In a recent screening of migrant populations in Belgium, the use of HBsAg POCT vs venipuncture testing led to a dramatic increase in linkage to care (from 34% to 86% (18)). Hence, whilst we still need to refine the utility of HBcrAg in broader settings, we need to acknowledge the need for faster turnaround in diagnosis and its association with increased linkage to care.

Limitations

We have evaluated HBcrAg in relatively small cohorts, in disparate geographical settings. There are important differences between populations which we have captured (demographics, HIV coinfection, treatment status), but also many unmeasured factors (differences in viral genotype, host genetics, comorbidity, environmental exposures) that can influence host and viral biomarkers

and outcomes of infection. Further exploration of the impact of HIV status would require larger numbers and include careful assessment of treatment duration. Developing insights into whether HBcrAg could be a surrogate marker for treatment eligibility requires ongoing assessment, ideally recruiting larger cohorts of treatment-naive individuals and measuring CrAg head-to-head with other eligibility criteria. This landscape is changing as new treatment guidelines are released which relax eligibility for treatment and therefore reduce the need for additional biomarkers.

Currently, HBcrAg CLEIA is not available in most settings and comes at a high cost, and the HBcrAg POCT is not commercially available. In our laboratory data set, running serial dilutions added to this cost for samples with HBcrAg above the upper limit of quantification (although this refined quantification of high levels may not be informative if the assay were to be deployed in more routine practice). Even if a POCT becomes accessible, the cost of procurement could be a barrier to its widespread use, as resources must be prioritised for scale-up of testing and monitoring using established tools.

Conclusions

Overall, even if absolute HBcrAg levels might be consistent in between geographical locations, associations with HBV VL seem not to be, suggesting the HBcrAg cannot and should not be used in similar ways in different geographical groups. In addition, contrary to most literature, we did not observe correlation with liver disease outcomes in our cohort, questioning the relevance of HBcrAg in this aspect.

TABLES

Table 1: Characteristis of two cohorts of adults with chronic hepatitis B virus infection based in South Africa (SA) and the United Kingdom (UK).

Characteristic	N	UK Cohort N = 142[1]	SA Cohort N = 211[1]	p-value[2]
Sex	333			0.7
Female		56 (46%)	92 (44%)	
Male		66 (54%)	119 (56%)	
Age (years)	332	40 (36, 49)	39 (34, 50)	0.4
Ethnicity	314			**<0.001**
Asian		52 (50%)	2 (1.0%)	
Black African		24 (23%)	143 (68%)	
White		29 (28%)	4 (1.9%)	
Mixed Race		0 (0%)	59 (28%)	
Other		0 (0%)	1 (0.5%)	
HIV status	339			**<0.001**
Negative		126 (98%)	92 (44%)	
Positive		3 (2.3%)	118 (56%)	
NA Therapy	334			**<0.001**
No		95 (69%)	68 (35%)	
Yes		42 (31%)	129 (65%)	
HBcrAg (log$_{10}$U/mL)	353	3.40 (2.90, 4.00)	3.57 (2.70, 6.80)	0.10
HBcrAg Group (log$_{10}$U/mL)	353			**<0.001**
<3.6		111 (53%)	85 (60%)	
3.6-4.8		23 (11%)	38 (27%)	
4.8 - 5.3		7 (3.3%)	6 (4.2%)	
>5.3		70 (33%)	13 (9.2%)	
ALT (U/L)	285	26 (18, 44)	29 (21, 40)	0.4
HBeAg status	276			**<0.001**
Negative		120 (88%)	100 (71%)	
Positive		16 (12%)	40 (29%)	
HBV DNA (log$_{10}$IU/ml)	312	2.54 (0.00, 3.37)	2.15 (1.30, 4.91)	0.3
HBV DNA Group, (IU/ml)	312			**<0.001**
<2000		104 (73%)	114 (67%)	
2000 - 20000		26 (18%)	10 (5.9%)	
20,000 - 200,000		4 (2.8%)	9 (5.3%)	
>200,000		8 (5.6%)	37 (22%)	
Undetectable DNA (<20 IU/ml)	312	46 (32%)	41 (24%)	0.10

[1]n (%); Median (IQR)

[2]Pearson's Chi-squared test; Wilcoxon rank sum test; Fisher's exact test

n - number, HIV - human immunodeficiency virus, NA - nucleoside analogue, HBcrAg - Hepatitis B core related antigen, HBeAg - hepatitis B 'e' antigen.

Table 2: Relationship between HBcrAg and demographic, laboratory and imaging characteristics of adults living with chronic HBV infection in the United Kingdom (UK) and South Africa (SA)

	UK cohort (N=142)	SA cohort (N=211)
Demographic characteristics		
Age	**R^2 -0.22 (p = 0.014)**	**R^2 -0.17 (p = 0.013)**
Sex	P = 0.64	P = 0.79
Routine laboratory biomarkers		
ALT	**R^2 0.38 (p < 0.001)**	**R^2 0.2 (p = 0.01)**
HBV DNA	**R^2 0.41 (p <0.001)**	**R^2 0.7 (p <0.001)**
Immunological biomarkers		
IL-21	R^2 -0.028 (p = 0.83)	R^2 0.0035 (p = 0.97)
IP-10	R^2 0.14 (p = 0.28)	R^2 0.18 (p = 0.08)
PD-1	R^2 0.14 (p = 0.28)	R^2 0.03 (p = 0.78)
Liver fibrosis assessment		
Elastography score (kPa)	R^2 -0.12 (p = 0.24)	R^2 0.15 (p = 0.24)
Fib-4	R^2 0.15 (p = 0.34)	R^2 -0.13 (p = 0.2)
APRI	R^2 0.23 (p = 0.13)	R^2 0.12 (p = 0.23)
HIV Status	**	**p<0.001**
Treatment Status	p=0.05	p=0.26

R^2 and p values calculated using Pearsons correlation coefficient
** Only n= 3 in the UK population, so we were unable to evaluate this.

Table 3: Sensitivity and specificity of HBeAg and HBcrAg levels as predictors of clinically significant HBV DNA viral load levels in cohorts in the United Kingdom (UK) and South Africa (SA). This only includes those off antiviral treatment.

Viral load threshold	HBV DNA level $(\log_{10}\text{IU/ml})$	UK cohort		SA cohort	
HBcrAg ($\log_{10}$U/ml)		**Sensitivity**	**Specificity**	**Sensitivity**	**Specificity**
≥5.3	>200,000	100%	100%	88%	88%
≥4.8	>20,000	67%	98%	89%	93%
≥3.6	>2000	44%	61%	83%	83%
HBcrAg POCT positive (HBcrAg ≥ 4.3 $\log_{10}$U/ml)		**Sensitivity**	**Specificity**	**Sensitivity**	**Specificity**
Positive	>200,000	100%	92%	94%	88%
Positive	>20,000	67%	92%	89%	92%
Positive	>2000	32%	93%	74%	91%

Table 4: Odds ratio of increasing HBcrAg with liver disease outcomes accounting for age, HBeAg and HBV VL. Odd ratios (natural logarithm scale) are displayed with associated p-values for each cohort or for the ratio of ratios in between the cohorts.

	UK cohort	SA cohort	UK vs SA
Elastography			
Fibrosis	-0.12 (p=0.84)	-0.06 (p=0.93)	0.06 (p= 0.93)
Cirrhosis	-0.65 (p=0.33)	-0.28 (p= 0.69)	0.37 (p= 0.56)
APRI			
Fibrosis	1.04 (p=0.48)	0.60 (p=0.66)	0.44 (p= 0.58)
Cirrhosis	0.19 (p=0.91)	0.02 (p=0.99)	0.17 (p= 0.82)
FIB-4			
Fibrosis	0.53 (p=0.75)	0.26 (p=0.85)	0.27 (p= 0.73)
Cirrhosis	0.25 (p=0.86)	-0.08 (p=0.95)	0.33 (p=0.68)
ALT - Liver Inflammation	0.48 (p=0.21)	0.32 (p=0.39)	0.16 (p=0.61)

FIGURES

Figure 1: Schematic to show the known and potential relationships between HBcrAg and other viral, host and environmental factors. (A) External factors which may influence HBcrAg; (B) Research questions to determine the potential utility of HBcrAg measurement. Figure created in Biorender with a licence to publish.

Figure 2: HBcrAg distribution in adults living with chronic hepatitis B (CHB) in South Africa (SA) and the United Kingdom (UK): A: UK cohort, all patients, B: SA cohort, all patients, C: UK cohort split by HBeAg status, D: SA cohort split by HBeAg status, E: UK cohort split by detectable vs undetectable HBV DNA, F: SA cohort split by detectable vs undetectable HBV DNA. Median HBcrAg value is shown along with interquartile range (IQR) by a boxplot inside the violin plot. Wilcoxon test for significance is shown.

Figure 3: Relationship between HBcrAg and HBV DNA in adults living with chronic hepatitis B infection, in the United Kingdom (UK) and South Africa (SA). Panels (A) and (B) show all individuals, (C) and (D) show only HBeAg negative. Pearson correlation coefficient shown.

Figure 4: Relationship between HBcrAg and inflammation based on alanine aspartate transferase (ALT) and immune cytokines (IP10, IL21 and PD1) in adults with chronic hepatitis B infection. UK cohort (A, C, E, G), South African cohort (B, D, F, H) . Pearson's correlation is shown.

References

1. World Health Organization Global hepatitis report 2024: action for access in low- and middle-income countries. https://www.who.int/publications/i/item/9789240091672. ISBN: 978-92-4-009167-2.

2. Goal 3 [Internet]. Available from: https://sdgs.un.org/goals/goal3

3. Lampertico P, Agarwal K, Berg T, Buti M, Janssen HLA, Papatheodoridis G, et al. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–98.

4. Overview | Hepatitis B (chronic): diagnosis and management | Guidance | NICE. [cited 2020 Nov 11]; Available from: https://www.nice.org.uk/guidance/cg165

5. Wai -I H, Ang Y, Heng -N An S, Un -F An Y, Iaw L, An -L In S, et al. The New England Journal of Medicine HEPATITIS B e ANTIGEN AND THE RISK OF HEPATOCELLULAR CARCINOMA Background The presence of hepatitis B e antigen. Vol. 347. 2002.

6. Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, et al. Serum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads. Hepatology. 2013;57:441–50.

7. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006 Jan 4;295(1):65–73.

8. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection. Geneva: World Health Organization; 2024. Licence: CC BYNC-SA 3.0. https://www.who.int/publications/i/item/9789240090903.

9. Wu JW, Kao JH, Tseng TC. Three heads are better than two: Hepatitis b core-related antigen as a new predictor of hepatitis b virus-related hepatocellular carcinoma. Clin Mol Hepatol [Internet]. 2021 Jul 1;27(3). Available from: https://pubmed.ncbi.nlm.nih.gov/33618507/

10. Mak LY, Wong DKH, Cheung KS, Seto WK, Lai CL, Yuen MF. Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection [Internet]. Vol. 47, Alimentary Pharmacology and Therapeutics. Blackwell Publishing Ltd; 2018. p. 43–54. Available from: http://dx.doi.org/10.1111/apt.14376

11. Chang KC, Lin MT, Wang JH, Hung CH, Chen CH, Chiu SYH, et al. HBcrAg Predicts Hepatocellular Carcinoma Development in Chronic B Hepatitis Related Liver Cirrhosis Patients Undergoing Long-Term Effective Anti-Viral. Viruses [Internet]. 2022 Nov 29;14(12). Available from: http://dx.doi.org/10.3390/v14122671

12. Ghany MG, King WC, Lisker-Melman M, Lok ASF, Terrault N, Janssen HLA, et al. Comparison of HBV RNA and Hepatitis B Core Related Antigen With Conventional HBV Markers Among Untreated Adults With Chronic Hepatitis B in North America. Hepatology. 2021;74(5):2021.

13. Testoni B, Lebossé F, Scholtes C, Berby F, Miaglia C, Subic M, et al. Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients. J Hepatol. 2019 Apr 1;70(4):615–25.

14. Afifi AM, Elgenidy A, Hashim M, Awad AK, Jalal PK. Hepatitis B virus core-related antigen (HBcrAg) as a prognostic marker for the development of hepatocellular carcinoma: A mini systematic review of the literature. Rev Med Virol. 2022 Nov;32(6):e2353.

15. Carey I, Gersch J, Wang B, Moigboi C, Kuhns M, Cloherty G, et al. Pregenomic HBV RNA and Hepatitis B Core-Related Antigen Predict Outcomes in Hepatitis B e Antigen–Negative Chronic Hepatitis B Patients Suppressed on Nucleos(T)ide Analogue Therapy. Hepatology. 2020 Jul 1;72(1):42–57.

16. Shimakawa Y, Ndow G, Njie R, Njai HF, Takahashi K, Akbar SMF, et al. Hepatitis B core-related antigen: An alternative to hepatitis B Virus DNA to assess treatment eligibility in Africa. Clin Infect Dis. 2020 Mar 17;70(7):1442–52.

17. Shimakawa Y, Ndow G, Kaneko A, Aoyagi K, Lemoine M, Tanaka Y, et al. Rapid point-of-care test for hepatitis B core-related antigen to diagnose high viral load in resource-limited settings. Clin Gastroenterol Hepatol [Internet]. 2022 Jun;0(0). Available from: http://www.cghjournal.org/article/S1542356522005547/fulltext

18. Ho E, Michielsen P, Van Damme P, Ieven M, Veldhuijzen I, Vanwolleghem T. Point-of-Care Tests for Hepatitis B Are Associated with A Higher Linkage to Care and Lower Cost Compared to Venepuncture Sampling During Outreach Screenings in an Asian Migrant Population. Ann Glob Health. 2020 Jul 16;86(1):81.

19. Peng G, Li S, Wu W, Tan X, Chen Y, Chen Z. PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients. Mol Immunol. 2008 Feb;45(4):963–70.

20. Li Y, Tang L, Hou J. Role of interleukin-21 in HBV infection: friend or foe? Cell Mol Immunol. 2015 May;12(3):303–8.

21. Wang Y, Yu W, Shen C, Wang W, Zhang L, Liu F, et al. Predictive Value of Serum IFN-γ inducible Protein-10 and IFN-γ/IL-4 Ratio for Liver Fibrosis Progression in CHB Patients. Sci Rep. 2017 Jan 9;7:40404.

22. Downs LOLO, Smith DADA, Lumley SFSF, Patel M, McNaughton ALALAL, Mokaya J, et al. Electronic Health Informatics Data To Describe Clearance Dynamics of Hepatitis B Surface Antigen (HBsAg) and e Antigen (HBeAg) in Chronic Hepatitis B Virus Infection. Moscona A, editor. MBio [Internet]. 2019 Jun 25;10(3). Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC6593400

23. McNaughton AL, Roberts HE, Bonsall D, de Cesare M, Mokaya J, Lumley SF, et al. Illumina and Nanopore methods for whole genome sequencing of hepatitis B virus (HBV). Sci Rep. 2019 May 8;9(1):7081.

24. Mokaya J, Maponga TG, McNaughton AL, Van Schalkwyk M, Hugo S, Singer JB, et al. Evidence of tenofovir resistance in chronic hepatitis B virus (HBV) infection: An observational case series of South African adults. J Clin Virol. 2020 Aug;129:104548.

25. Maponga TG, McNaughton AL, van Schalkwyk M, Hugo S, Nwankwo C, Taljaard J, et al. Treatment advantage in HBV/HIV coinfection compared to HBV monoinfection in a South African cohort. J Infect. 2020 Jul;81(1):121–30.

26. Matthews P, Maponga T, Goedhals D. OXSAHEP Project Report [Internet]. 2023. Available from: https://figshare.com/articles/presentation/OXSAHEP_Project_Report/22090628

27. Programmes STI. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection [Internet]. World Health Organization; 2015 [cited 2023 Dec 13]. Available from: https://www.who.int/publications/i/item/9789241549059

28. Kosmidis I, Firth D. Jeffreys-prior penalty, finiteness and shrinkage in binomial-response generalized linear models. Biometrika. 2021 Mar 2;108(1):71–82.

29. Tada T, Kumada T, Toyoda H, Kobayashi N, Akita T, Tanaka J. Hepatitis B virus core-related antigen levels predict progression to liver cirrhosis in hepatitis B carriers. J Gastroenterol Hepatol. 2018 Apr 1;33(4):918–25.

30. Chang XJ, Sun C, Chen Y, Li XD, Yu ZJ, Dong Z, et al. On-treatment monitoring of liver fibrosis with serum hepatitis B core-related antigen in chronic hepatitis B. World J Gastroenterol. 2019 Aug 28;25(32):4764–78.